Arrowhead Pharmaceuticals (ARWR) EBT Margin (2010 - 2026)
Arrowhead Pharmaceuticals (ARWR) posted EBT Margin of 186.56% for Q1 2026, down 1842.37% on a QoQ basis from 10.71% in Q4 2025, and down 25467.0% year-over-year from N/an in Q1 2025.
Arrowhead Pharmaceuticals (ARWR) EBT Margin (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals' EBT Margin history runs 17 years deep, the most recent figure standing at 186.56% for Q1 2026.
- Quarterly EBT Margin fell 25467.0% year-over-year to 186.56% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 40.56% (down 1263.0% YoY) and the FY2025 annual result came in at 6.21%, up 1725375.0% from the prior year.
- EBT Margin was 186.56% for Q1 2026 at Arrowhead Pharmaceuticals, down from 10.71% in the prior quarter.
- Across five years, EBT Margin topped out at 68.11% in Q1 2025 and bottomed at 7004.6% in Q4 2024.
- A 5-year average of 961.91% and a median of 204.42% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin sank 383881 bps — and 2025, when it soared 701531 bps.
- Arrowhead Pharmaceuticals' EBT Margin stood at 66.82% in 2022, then sank by 5745 bps to 3905.63% in 2023, then plunged by 79 bps to 7004.6% in 2024, then surged by 100 bps to 10.71% in 2025, then slumped by 1842 bps to 186.56% in 2026.
- Business Quant data shows ARWR's EBT Margin at 186.56% in Q1 2026, 10.71% in Q4 2025, and 14.08% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arrowhead Pharmaceuticals | 11.98 Bn | 10.18 Bn | - | -186.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -186.56% |
| Dec 31, 2025 | 10.71% |
| Sep 30, 2025 | 14.08% |
| Jun 30, 2025 | -644.97% |
| Mar 31, 2025 | 68.11% |
| Dec 31, 2024 | -7,004.60% |
| Dec 31, 2023 | -3,905.63% |
| Sep 30, 2023 | -677.08% |
| Jun 30, 2023 | -653.29% |
| Mar 31, 2023 | 32.60% |
| Dec 31, 2022 | -66.82% |
| Sep 30, 2022 | -260.20% |
| Jun 30, 2022 | -222.28% |
| Mar 31, 2022 | 29.23% |
| Dec 31, 2021 | -229.13% |
| Sep 30, 2021 | -165.54% |
| Jun 30, 2021 | -65.21% |
| Mar 31, 2021 | -81.73% |
| Dec 31, 2020 | -97.32% |
| Sep 30, 2020 | -634.51% |